LUN.CO : Summary for H. Lundbeck A/S - Yahoo Finance

U.S. Markets closed

H. Lundbeck A/S (LUN.CO)


Copenhagen - Copenhagen Delayed Price. Currency in DKK
Add to watchlist
286.10-6.80 (-2.32%)
At close: 4:59PM CET
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close292.90
Open291.80
Bid286.00 x
Ask286.30 x
Day's Range285.80 - 291.80
52 Week Range209.40 - 307.40
Volume517,073
Avg. Volume284,322
Market Cap56.47B
Beta-0.74
PE Ratio (TTM)46.60
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield0.00 (0.00%)
Ex-Dividend DateN/A
1y Target EstN/A
  • Bloomberg8 hours ago

    Lundbeck Mulls Alzheimer's Combo Therapy in Wake of Drug Failure

    H. Lundbeck A/S is looking at ways to develop combination therapies for Alzheimer’s disease as the Danish brain-disorder specialist presses forward despite recent failures in late-stage patient trials....

  • Thomson Reuters StreetEvents19 days ago

    Edited Transcript of LUN.CO earnings conference call or presentation 8-Feb-17 12:00pm GMT

    Q4 2016 H Lundbeck A/S Earnings Call

  • Reuterslast month

    Lundbeck bets on shark antibodies for new brain drugs

    Danish drugmaker Lundbeck is betting that shark antibodies may offer a new way of getting drugs into the brain to fight Alzheimer's and other diseases, after successful early research with privately owned U.S. biotech firm Ossianix. The two companies said on Thursday that Lundbeck had made an undisclosed payment to Ossianix, which has labs in Britain, following experiments in mice showing the effective transfer of potential drugs across the blood-brain barrier. Getting modern large-molecule medicines across the barrier that protects the brain is a major challenge for drug developers.